# Access to Innovative Hematological Treatments in Morocco: Delays, Barriers, and a Public Health Concern

## TL;DR

In Morocco, patients with chronic lymphocytic leukemia face delays and barriers in accessing new treatments, leading to reliance on outdated chemotherapy.

## Contribution

The paper identifies and analyzes the specific barriers to innovative hematological treatments in Morocco, emphasizing public health implications.

## Key findings

- Limited availability of Bruton tyrosine kinase and BCL-2 inhibitors in Morocco persists.
- Regulatory delays and financial barriers hinder access to novel therapies.
- Many patients still receive conventional chemotherapy despite international guidelines.

## Abstract

Therapeutic advances in hematology, particularly the introduction of targeted agents, have substantially improved outcomes of patients with chronic lymphocytic leukemia (CLL). However, access to these innovative treatments remains uneven across regions, especially in middle-income countries. In Morocco, limited availability of Bruton tyrosine kinase and BCL-2 inhibitors, delays in regulatory approval, and financial and reimbursement barriers continue to shape real-world treatment strategies. As a result, many patients still receive conventional chemotherapy-based regimens despite international guideline recommendations favoring chemotherapy-free approaches. This editorial highlights the current gaps between evidence-based standards and clinical practice in Morocco, reviews available epidemiological data, and discusses the regulatory and structural obstacles affecting timely access to novel therapies. Addressing these disparities is essential to improve equity of care and ensure that therapeutic progress translates into meaningful clinical benefit for all patients with CLL.